Global Live Attenuated Influenza Vaccine (LAIV) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Live Attenuated Influenza Vaccine (LAIV) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Live Attenuated Influenza Vaccine (LAIV) market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.
The Live Attenuated Influenza Vaccine (LAIV) market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
Hospital occupied for % of the Live Attenuated Influenza Vaccine (LAIV) global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Trivalent Flu Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Live Attenuated Influenza Vaccine (LAIV) include Sanofi Pasteur, AstraZeneca, CSL, Abbott and GlaxoSmithKline, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Key Features of This Report:
This report provides in-depth analysis of the global Live Attenuated Influenza Vaccine (LAIV) market, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year
Main Live Attenuated Influenza Vaccine (LAIV) manufacturers’ industry ranking, sales, revenue, price, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the global Live Attenuated Influenza Vaccine (LAIV) market based on the following parameters – headquarters, production locations, products portfolio, Live Attenuated Influenza Vaccine (LAIV) revenue, sales, average price and gross margin, recent developments.
Evaluation and forecast the Live Attenuated Influenza Vaccine (LAIV) market size, projected growth trends, and corresponding market share analysis by type, by application, and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market Segmentation
Live Attenuated Influenza Vaccine (LAIV) market is split by Type and by Application. For the period 2017-2028, the growth among segments provides accurate calculations and forecasts for sales by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2028; USD Million)
Chapter 1, to describe Live Attenuated Influenza Vaccine (LAIV) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Live Attenuated Influenza Vaccine (LAIV), with price, sales, revenue and global market share of Live Attenuated Influenza Vaccine (LAIV) from 2019 to 2022.
Chapter 3, the Live Attenuated Influenza Vaccine (LAIV) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live Attenuated Influenza Vaccine (LAIV) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Live Attenuated Influenza Vaccine (LAIV) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Live Attenuated Influenza Vaccine (LAIV).
Chapter 13, 14, and 15, to describe Live Attenuated Influenza Vaccine (LAIV) sales channel, distributors, customers, research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Live Attenuated Influenza Vaccine (LAIV) market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.
The Live Attenuated Influenza Vaccine (LAIV) market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
Hospital occupied for % of the Live Attenuated Influenza Vaccine (LAIV) global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Trivalent Flu Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Live Attenuated Influenza Vaccine (LAIV) include Sanofi Pasteur, AstraZeneca, CSL, Abbott and GlaxoSmithKline, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Key Features of This Report:
This report provides in-depth analysis of the global Live Attenuated Influenza Vaccine (LAIV) market, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year
Main Live Attenuated Influenza Vaccine (LAIV) manufacturers’ industry ranking, sales, revenue, price, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the global Live Attenuated Influenza Vaccine (LAIV) market based on the following parameters – headquarters, production locations, products portfolio, Live Attenuated Influenza Vaccine (LAIV) revenue, sales, average price and gross margin, recent developments.
Evaluation and forecast the Live Attenuated Influenza Vaccine (LAIV) market size, projected growth trends, and corresponding market share analysis by type, by application, and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market Segmentation
Live Attenuated Influenza Vaccine (LAIV) market is split by Type and by Application. For the period 2017-2028, the growth among segments provides accurate calculations and forecasts for sales by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2028; USD Million)
- Trivalent Flu Vaccine
- Quadrivalent Flu Vaccine
- Hospital
- Clinic
- Public Health Agency
- Other
- Sanofi Pasteur
- AstraZeneca
- CSL
- Abbott
- GlaxoSmithKline
- Serum Institute
- Fluenz Tetra
- Cytiva
- BioDiem
- FluMist
- GSK
- ChangChun High & New Technology
- BCHT Biotechnology
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Live Attenuated Influenza Vaccine (LAIV) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Live Attenuated Influenza Vaccine (LAIV), with price, sales, revenue and global market share of Live Attenuated Influenza Vaccine (LAIV) from 2019 to 2022.
Chapter 3, the Live Attenuated Influenza Vaccine (LAIV) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Live Attenuated Influenza Vaccine (LAIV) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Live Attenuated Influenza Vaccine (LAIV) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Live Attenuated Influenza Vaccine (LAIV).
Chapter 13, 14, and 15, to describe Live Attenuated Influenza Vaccine (LAIV) sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Live Attenuated Influenza Vaccine (LAIV) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Trivalent Flu Vaccine
1.2.3 Quadrivalent Flu Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Global Live Attenuated Influenza Vaccine (LAIV) Market Size & Forecast
1.4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume (2017-2028)
1.4.3 Global Live Attenuated Influenza Vaccine (LAIV) Price (2017-2028)
1.5 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity Analysis
1.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Total Production Capacity (2017-2028)
1.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
1.6.2 Live Attenuated Influenza Vaccine (LAIV) Market Restraints
1.6.3 Live Attenuated Influenza Vaccine (LAIV) Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 CSL
2.3.1 CSL Details
2.3.2 CSL Major Business
2.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Serum Institute
2.6.1 Serum Institute Details
2.6.2 Serum Institute Major Business
2.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Fluenz Tetra
2.7.1 Fluenz Tetra Details
2.7.2 Fluenz Tetra Major Business
2.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Cytiva
2.8.1 Cytiva Details
2.8.2 Cytiva Major Business
2.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 BioDiem
2.9.1 BioDiem Details
2.9.2 BioDiem Major Business
2.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 FluMist
2.10.1 FluMist Details
2.10.2 FluMist Major Business
2.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 GSK
2.11.1 GSK Details
2.11.2 GSK Major Business
2.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 ChangChun High & New Technology
2.12.1 ChangChun High & New Technology Details
2.12.2 ChangChun High & New Technology Major Business
2.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 BCHT Biotechnology
2.13.1 BCHT Biotechnology Details
2.13.2 BCHT Biotechnology Major Business
2.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) BREAKDOWN DATA BY MANUFACTURER
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Live Attenuated Influenza Vaccine (LAIV)
3.4 Market Concentration Rate
3.4.1 Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2021
3.4.2 Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2021
3.5 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Region (2017-2028)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2028)
4.2 North America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.3 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.4 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.5 South America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.6 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Type (2017-2028)
5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2017-2028)
5.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Application (2017-2028)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2017-2028)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
7.2 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
7.3 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
7.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
7.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
8.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
8.3 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
8.3.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
9.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
9.3 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
9.3.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
10.2 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
10.3 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
10.3.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
10.3.2 South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
11.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
11.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
11.3.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Live Attenuated Influenza Vaccine (LAIV) and Key Manufacturers
12.2 Manufacturing Costs Percentage of Live Attenuated Influenza Vaccine (LAIV)
12.3 Live Attenuated Influenza Vaccine (LAIV) Production Process
12.4 Live Attenuated Influenza Vaccine (LAIV) Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
13.3 Live Attenuated Influenza Vaccine (LAIV) Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
1.1 Live Attenuated Influenza Vaccine (LAIV) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Trivalent Flu Vaccine
1.2.3 Quadrivalent Flu Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Global Live Attenuated Influenza Vaccine (LAIV) Market Size & Forecast
1.4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume (2017-2028)
1.4.3 Global Live Attenuated Influenza Vaccine (LAIV) Price (2017-2028)
1.5 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity Analysis
1.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Total Production Capacity (2017-2028)
1.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
1.6.2 Live Attenuated Influenza Vaccine (LAIV) Market Restraints
1.6.3 Live Attenuated Influenza Vaccine (LAIV) Trends Analysis
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 CSL
2.3.1 CSL Details
2.3.2 CSL Major Business
2.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business
2.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Serum Institute
2.6.1 Serum Institute Details
2.6.2 Serum Institute Major Business
2.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Fluenz Tetra
2.7.1 Fluenz Tetra Details
2.7.2 Fluenz Tetra Major Business
2.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.7.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Cytiva
2.8.1 Cytiva Details
2.8.2 Cytiva Major Business
2.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 BioDiem
2.9.1 BioDiem Details
2.9.2 BioDiem Major Business
2.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 FluMist
2.10.1 FluMist Details
2.10.2 FluMist Major Business
2.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 GSK
2.11.1 GSK Details
2.11.2 GSK Major Business
2.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 ChangChun High & New Technology
2.12.1 ChangChun High & New Technology Details
2.12.2 ChangChun High & New Technology Major Business
2.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 BCHT Biotechnology
2.13.1 BCHT Biotechnology Details
2.13.2 BCHT Biotechnology Major Business
2.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
2.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) BREAKDOWN DATA BY MANUFACTURER
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Live Attenuated Influenza Vaccine (LAIV)
3.4 Market Concentration Rate
3.4.1 Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2021
3.4.2 Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer Market Share in 2021
3.5 Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Region (2017-2028)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2028)
4.2 North America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.3 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.4 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.5 South America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
4.6 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Type (2017-2028)
5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2017-2028)
5.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Application (2017-2028)
6.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2017-2028)
6.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
7.2 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
7.3 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
7.3.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
7.3.2 North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
8.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
8.3 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
8.3.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
9.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
9.3 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Region
9.3.1 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
10.2 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
10.3 South America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
10.3.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
10.3.2 South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2028)
11.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2028)
11.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Country
11.3.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Live Attenuated Influenza Vaccine (LAIV) and Key Manufacturers
12.2 Manufacturing Costs Percentage of Live Attenuated Influenza Vaccine (LAIV)
12.3 Live Attenuated Influenza Vaccine (LAIV) Production Process
12.4 Live Attenuated Influenza Vaccine (LAIV) Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
13.3 Live Attenuated Influenza Vaccine (LAIV) Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
LIST OF TABLES
Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 6. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 10. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. CSL Basic Information, Manufacturing Base and Competitors
Table 12. CSL Major Business
Table 13. CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 14. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Abbott Basic Information, Manufacturing Base and Competitors
Table 16. Abbott Major Business
Table 17. Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 18. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 20. GlaxoSmithKline Major Business
Table 21. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 22. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Serum Institute Basic Information, Manufacturing Base and Competitors
Table 24. Serum Institute Major Business
Table 25. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 26. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Fluenz Tetra Basic Information, Manufacturing Base and Competitors
Table 28. Fluenz Tetra Major Business
Table 29. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 30. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Cytiva Basic Information, Manufacturing Base and Competitors
Table 32. Cytiva Major Business
Table 33. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 34. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. BioDiem Basic Information, Manufacturing Base and Competitors
Table 36. BioDiem Major Business
Table 37. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 38. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. FluMist Basic Information, Manufacturing Base and Competitors
Table 40. FluMist Major Business
Table 41. FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 42. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. GSK Basic Information, Manufacturing Base and Competitors
Table 44. GSK Major Business
Table 45. GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 46. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. ChangChun High & New Technology Basic Information, Manufacturing Base and Competitors
Table 48. ChangChun High & New Technology Major Business
Table 49. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 50. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. BCHT Biotechnology Basic Information, Manufacturing Base and Competitors
Table 52. BCHT Biotechnology Major Business
Table 53. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 54. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 57. Market Position of Manufacturers in Live Attenuated Influenza Vaccine (LAIV), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 58. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Company, (K Units): 2020 VS 2021
Table 59. Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site of Key Manufacturer
Table 60. Live Attenuated Influenza Vaccine (LAIV) New Entrant and Capacity Expansion Plans
Table 61. Live Attenuated Influenza Vaccine (LAIV) Mergers & Acquisitions in the Past Five Years
Table 62. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 63. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 64. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 65. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 66. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 67. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 68. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2017-2022) & (USD Million)
Table 69. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2023-2028) & (USD Million)
Table 70. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2022) & (US$/Unit)
Table 71. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2023-2028) & (US$/Unit)
Table 72. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 73. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 74. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2017-2022) & (USD Million)
Table 75. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2023-2028) & (USD Million)
Table 76. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2022) & (US$/Unit)
Table 77. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2023-2028) & (US$/Unit)
Table 78. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 79. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 80. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 81. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 82. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 83. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 84. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 85. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 86. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 87. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 88. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 89. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 90. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 91. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 92. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 93. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 94. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 95. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 96. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 97. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 98. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 99. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 100. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 101. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 102. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 103. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 104. South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 105. South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 106. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 107. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 108. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 109. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 110. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 111. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 112. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 113. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 114. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 115. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 116. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 117. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 118. Live Attenuated Influenza Vaccine (LAIV) Raw Material
Table 119. Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV) Raw Materials
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
Table 123. Live Attenuated Influenza Vaccine (LAIV) Typical Customers
Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 6. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 10. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. CSL Basic Information, Manufacturing Base and Competitors
Table 12. CSL Major Business
Table 13. CSL Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 14. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Abbott Basic Information, Manufacturing Base and Competitors
Table 16. Abbott Major Business
Table 17. Abbott Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 18. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 20. GlaxoSmithKline Major Business
Table 21. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 22. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Serum Institute Basic Information, Manufacturing Base and Competitors
Table 24. Serum Institute Major Business
Table 25. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 26. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Fluenz Tetra Basic Information, Manufacturing Base and Competitors
Table 28. Fluenz Tetra Major Business
Table 29. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 30. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Cytiva Basic Information, Manufacturing Base and Competitors
Table 32. Cytiva Major Business
Table 33. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 34. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. BioDiem Basic Information, Manufacturing Base and Competitors
Table 36. BioDiem Major Business
Table 37. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 38. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. FluMist Basic Information, Manufacturing Base and Competitors
Table 40. FluMist Major Business
Table 41. FluMist Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 42. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. GSK Basic Information, Manufacturing Base and Competitors
Table 44. GSK Major Business
Table 45. GSK Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 46. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. ChangChun High & New Technology Basic Information, Manufacturing Base and Competitors
Table 48. ChangChun High & New Technology Major Business
Table 49. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 50. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. BCHT Biotechnology Basic Information, Manufacturing Base and Competitors
Table 52. BCHT Biotechnology Major Business
Table 53. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product and Services
Table 54. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 57. Market Position of Manufacturers in Live Attenuated Influenza Vaccine (LAIV), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 58. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Company, (K Units): 2020 VS 2021
Table 59. Head Office and Live Attenuated Influenza Vaccine (LAIV) Production Site of Key Manufacturer
Table 60. Live Attenuated Influenza Vaccine (LAIV) New Entrant and Capacity Expansion Plans
Table 61. Live Attenuated Influenza Vaccine (LAIV) Mergers & Acquisitions in the Past Five Years
Table 62. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 63. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 64. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 65. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 66. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 67. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 68. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2017-2022) & (USD Million)
Table 69. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2023-2028) & (USD Million)
Table 70. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2022) & (US$/Unit)
Table 71. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2023-2028) & (US$/Unit)
Table 72. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 73. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 74. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2017-2022) & (USD Million)
Table 75. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2023-2028) & (USD Million)
Table 76. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2022) & (US$/Unit)
Table 77. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2023-2028) & (US$/Unit)
Table 78. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 79. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 80. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 81. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 82. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 83. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 84. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 85. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 86. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 87. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 88. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 89. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 90. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 91. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 92. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 93. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 94. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 95. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 96. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 97. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 98. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 99. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 100. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 101. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 102. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022) & (K Units)
Table 103. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2023-2028) & (K Units)
Table 104. South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022) & (USD Million)
Table 105. South America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2023-2028) & (USD Million)
Table 106. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 107. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 108. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 109. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 110. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022) & (K Units)
Table 111. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2023-2028) & (K Units)
Table 112. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022) & (USD Million)
Table 113. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2023-2028) & (USD Million)
Table 114. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2017-2022) & (K Units)
Table 115. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2023-2028) & (K Units)
Table 116. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2017-2022) & (K Units)
Table 117. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2023-2028) & (K Units)
Table 118. Live Attenuated Influenza Vaccine (LAIV) Raw Material
Table 119. Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV) Raw Materials
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Live Attenuated Influenza Vaccine (LAIV) Typical Distributors
Table 123. Live Attenuated Influenza Vaccine (LAIV) Typical Customers
LIST OF FIGURES
Figure 1. Live Attenuated Influenza Vaccine (LAIV) Picture
Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type in 2021
Figure 3. Trivalent Flu Vaccine
Figure 4. Quadrivalent Flu Vaccine
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Public Health Agency
Figure 9. Other
Figure 10. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Sales (2017-2028) & (K Units)
Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Price (2017-2028) & (US$/Unit)
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity (2017-2028) & (K Units)
Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
Figure 17. Live Attenuated Influenza Vaccine (LAIV) Market Restraints
Figure 18. Live Attenuated Influenza Vaccine (LAIV) Market Trends
Figure 19. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturer in 2021
Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturer in 2021
Figure 21. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 26. North America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 27. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 29. South America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2017-2028)
Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2017-2028)
Figure 36. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 38. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 39. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 40. North America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 41. United States Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 45. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 47. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 48. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 57. China Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 64. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 65. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 66. South America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV) in 2021
Figure 78. Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
Figure 79. Live Attenuated Influenza Vaccine (LAIV) Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Figure 1. Live Attenuated Influenza Vaccine (LAIV) Picture
Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type in 2021
Figure 3. Trivalent Flu Vaccine
Figure 4. Quadrivalent Flu Vaccine
Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Public Health Agency
Figure 9. Other
Figure 10. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Sales (2017-2028) & (K Units)
Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Price (2017-2028) & (US$/Unit)
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity (2017-2028) & (K Units)
Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
Figure 17. Live Attenuated Influenza Vaccine (LAIV) Market Restraints
Figure 18. Live Attenuated Influenza Vaccine (LAIV) Market Trends
Figure 19. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturer in 2021
Figure 20. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturer in 2021
Figure 21. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Live Attenuated Influenza Vaccine (LAIV) Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 26. North America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 27. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 29. South America Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue (2017-2028) & (USD Million)
Figure 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 32. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2017-2028)
Figure 33. Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 35. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2017-2028)
Figure 36. Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 38. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 39. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 40. North America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 41. United States Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 45. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 46. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 47. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 48. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 57. China Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 64. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 65. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2017-2028)
Figure 66. South America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Live Attenuated Influenza Vaccine (LAIV) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV) in 2021
Figure 78. Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
Figure 79. Live Attenuated Influenza Vaccine (LAIV) Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
